ROCKVILLE, Md., May 3 /PRNewswire/ -- Accelovance, a Rockville, Maryland based clinical services company is pleased to name Robert C. deGroof, Ph.D. as Chief Scientific Officer. In this role, Dr. deGroof will bring his 25 years of pharmaceutical industry experience to lead all clinical and regulatory services for current and upcoming research studies.
“We are excited to have Bob formally join us from his previous consultant role. His experience with pharma and biotech will help position our company to deliver a higher level of service to our clients and strengthen our core competencies. This addition is an integral step in moving Accelovance into its next phase of growth,” remarked Stephen J. Trevisan, CEO and President of Accelovance.
Before arriving at Accelovance, Dr. deGroof served as Senior Vice President of Drug Development for Ambit Biosciences where he managed clinical, toxicology, manufacturing, quality assurance and regulatory affairs for all of their products. He had similar responsibilities as the Senior Vice President of Scientific Affairs at Alteon Inc. Prior to Alteon, Inc., he held leadership positions in drug development and regulatory affairs at Johnson and Johnson and Bristol-Myers Squibb. Additionally, for more than 10 years Dr. deGroof operated an independent consultancy for strategic development of prescription and non-prescription pharmaceuticals. Dr. deGroof held academic appointments at the medical schools of the University of Pennsylvania and Thomas Jefferson University. He holds a Ph.D. in Physiology and Pharmacology from Duke University and a B.S. in Electrical Engineering from the University of Florida.
“It is exciting to join an entrepreneurial and client focused company like Accelovance. My goal is to help deliver on our client’s needs and expand our service offerings over time,” commented Dr. deGroof on his new role.
Headquartered in Rockville, Maryland, Accelovance is a privately held company that has developed a unique system for delivering quality, on time, and cost effective clinical studies. In China, the Company operates through its wholly-owned foreign enterprise in Beijing as a contract research organization (CRO). Accelovance is focused on optimizing the quality and productivity of multiple clinical sites, through strong central management and targeted pro-active patient recruitment. Delivering high quality and timely clinical trial support services, Accelovance is committed to understanding and meeting its clients needs to contribute to their success.
For more information, visit the company’s website at http://www.accelovance.com.
CONTACT: Media: Garrett D. Smith at 240.238.4914
Accelovance
CONTACT: Garrett D. Smith of Accelovance, +1-240-238-4914
Web site: http://www.accelovance.com/
